A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties
Sign Up to like & getrecommendations! Published in 2022 at "mAbs"
DOI: 10.1080/19420862.2022.2044435
Abstract: ABSTRACT Targeting PD1/PDL1 with blocking antibodies for cancer therapy has shown promising benefits in the clinic, but only approximately 20–30% of patients develop durable clinical responses to the treatment. Bispecific antibodies (BsAbs) that combine PD1/PDL1… read more here.
Keywords: igg like; immune checkpoint; desired igg; anti pd1 ... See more keywords